Compare NP & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NP | TLX |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | Australia |
| Employees | 60 | 1184 |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.6B |
| IPO Year | N/A | N/A |
| Metric | NP | TLX |
|---|---|---|
| Price | $25.08 | $9.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 4 |
| Target Price | ★ $28.17 | $21.13 |
| AVG Volume (30 Days) | ★ 864.9K | 98.2K |
| Earning Date | 04-22-2026 | 08-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.84 | N/A |
| Revenue Next Year | $15.80 | N/A |
| P/E Ratio | ★ N/A | $150.33 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.78 | $6.28 |
| 52 Week High | $31.75 | $18.13 |
| Indicator | NP | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 42.00 | 34.04 |
| Support Level | $24.16 | $8.85 |
| Resistance Level | $26.85 | $9.92 |
| Average True Range (ATR) | 1.46 | 0.23 |
| MACD | -0.32 | -0.16 |
| Stochastic Oscillator | 10.25 | 1.11 |
Neptune Insurance Holdings Inc is a high-growth, profitable, data-driven MGA that offers residential and commercial insurance products, including primary flood insurance, excess flood insurance and parametric earthquake insurance, distributed through a nationwide network of agencies in the United States. The company underwrites and administers the issuance of insurance policies on behalf of a diverse panel of insurance and reinsurance companies and does not take any balance sheet insurance risk or have claims handling responsibility relating to the policies it sells.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.